Societe Generale’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Societe Generale’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$53K	Buy	+22,117	New	+$80K	﹤0.01%	2451

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Societe Generale's AST Position: Q2 2016 in Review

Societe Generale opened a new position in Asterias Biotherapeutics Inc. Series A (AST) in Q2 2016: 22,117 shares worth $53K. The stake represents ﹤0.01% of the portfolio and ranks #2451 among its holdings.

66 funds tracked by Wall St. Rank hold AST as of Q2 2016.

Societe Generale held 22,117 shares of Asterias Biotherapeutics Inc. Series A worth $53K as of Q2 2016.
Asterias Biotherapeutics Inc. Series A was a new Societe Generale position in Q2 2016.
Asterias Biotherapeutics Inc. Series A made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2451 holding.
66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.